Semaglutide vs. Tirzepatide: Which GLP-1 Medication Is Right for You?

Two highly effective GLP-1 medications are currently available for physician-supervised medical weight loss: semaglutide and tirzepatide. Both are once-weekly injectable medications. Both produce meaningful weight loss when combined with appropriate diet and physician monitoring. The clinical trials supporting each are among the largest and most rigorous in obesity medicine history.

The question is not which is better in general — it is which is more appropriate for you, specifically. This article compares the two medications on mechanism, clinical trial outcomes, side effect profiles, cost, and how physicians make the prescribing decision. For a full overview of physician-supervised medical weight loss at Vitality Texas, see our weight loss program page.

How They Work: Mechanism Differences

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone produced in the gut after eating. It signals the pancreas to release insulin in response to glucose, slows gastric emptying, and acts on the brain's appetite regulation centers — reducing hunger and increasing the sense of fullness after meals. Semaglutide mimics and amplifies this natural signal at a sustained, pharmacological level.

Tirzepatide is a dual GIP and GLP-1 receptor agonist. In addition to activating GLP-1 receptors, tirzepatide also activates GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP is a second gut hormone with its own role in insulin secretion, fat metabolism, and energy balance. The dual mechanism adds a second hunger and satiety pathway to the single pathway that semaglutide targets.

Whether dual targeting produces meaningfully greater weight loss in an individual patient depends on how their physiology responds to each pathway. Clinical trial data — discussed in the next section — suggests that on average, the dual mechanism produces greater weight reduction. But “on average” is a population result, not a guarantee for any individual.

Weight Loss Results: What Clinical Trials Show

Three major trials provide the most clinically relevant data for comparing these medications.

STEP 1 (semaglutide 2.4 mg, 68 weeks) — In this pivotal randomized controlled trial, participants treated with semaglutide 2.4 mg achieved an average body weight reduction of 14.9% compared to 2.4% with placebo (Wilding et al., NEJM 2021). This established semaglutide as one of the most effective medications for weight loss in clinical history to that point.

SURMOUNT-1 (tirzepatide 15 mg, 72 weeks) — The pivotal tirzepatide trial found an average body weight reduction of 20.9% at the highest dose compared to 3.1% with placebo (Jastreboff et al., NEJM2022). This exceeded semaglutide's STEP 1 results, but comparing across separate trials with different populations and durations has significant methodological limitations.

SURMOUNT-5 (head-to-head, 2025) — This is the clinically decisive comparison: a direct randomized controlled trial with both medications tested in the same population under the same conditions. In the SURMOUNT-5 trial (Aronne et al., NEJM 2025), tirzepatide produced an average body weight reduction of 20.2% versus 13.7% with semaglutide at 72 weeks. Among tirzepatide participants, 63% achieved 20% or more body weight reduction, compared to 28% of semaglutide participants.

Individual results vary. These are trial averages in populations of people with obesity or overweight plus at least one weight-related health condition. Your actual results depend on your baseline, your adherence to the dosing protocol, diet, activity level, and how your physiology responds to each medication.

Side Effect Comparison

Both medications share a fundamentally similar side effect profile. The most commonly reported effects for both semaglutide and tirzepatide are:

• Nausea (most common, particularly during dose escalation)
• Vomiting
• Constipation
• Diarrhea

In SURMOUNT-5, side effect rates were broadly comparable between the two medications. Some earlier studies noted slightly higher nausea rates with tirzepatide, though this finding has not been consistent across all comparisons. Both medications use a gradual titration schedule — starting at a low dose and increasing over weeks to months — specifically to minimize GI side effects during the adjustment period.

Individual tolerance varies considerably. Some patients experience minimal side effects on one medication and significant nausea on the other, without a clear pattern predictable before starting. Physician monitoring during the titration phase allows for dose adjustment if side effects are problematic.

Both medications share the same contraindications: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, or prior serious hypersensitivity reaction to the medication. A physician evaluation before prescribing identifies these and other relevant contraindications.

Cost Comparison

Brand-name list prices (publicly available from manufacturers as of 2025):

• Wegovy (semaglutide 2.4 mg, FDA-approved for chronic weight management): approximately $1,349/month list price
• Zepbound (tirzepatide, FDA-approved for chronic weight management): approximately $1,059/month list price

Compounded versions of both medications are available through 503A pharmacies at lower cost than brand-name products. Compounded semaglutide and tirzepatide are not FDA-approved products — they are distinct formulations prepared by compounding pharmacies. Cost varies by dose, pharmacy, and program structure.

Insurance rarely covers GLP-1 medications for weight loss, though some Medicare Part D plans and select commercial plans have added coverage as of 2025. HSA and FSA accounts are eligible for physician-prescribed medication and labs.

Your specific pricing at Vitality — including medication type, dose, labs, and monitoring — is reviewed in full at your free initial consultation. For a detailed breakdown of what semaglutide programs cost, see how much does semaglutide cost.

Which Medication Does Dr. Jaqua Recommend?

There is no single answer, and any provider who gives you one without evaluating you individually should be viewed with skepticism. The prescribing decision at Vitality depends on:

• Health history and contraindications — certain thyroid conditions, prior pancreatitis, and kidney disease affect which medications are appropriate
• Prior medication experience — patients who have previously tried semaglutide with suboptimal results may be better candidates for tirzepatide; patients new to GLP-1 therapy often start with semaglutide as a first-line option
• Insurance and cost considerations — coverage differences between the two medications affect real-world access
• Patient preference— when both options are clinically appropriate, the patient's informed preference is incorporated into the decision

SURMOUNT-5 data informs the recommendation when both medications are clinically appropriate options — the head-to-head trial data favoring tirzepatide on average weight loss is factored into the clinical conversation. But trial averages are population data; individual response varies.

Tirzepatide for Patients Who Have Plateaued on Semaglutide

A common clinical scenario: a patient achieves meaningful weight loss on semaglutide, reaches a plateau, and seeks options for continued progress. SURMOUNT-5 provides useful context here — the trial data suggests that patients who respond partially to GLP-1 receptor agonism alone may achieve further results with the addition of GIP receptor agonism.

Transitioning from semaglutide to tirzepatide is a clinical decision that requires physician oversight. The transition is not an abrupt switch — it involves a structured titration protocol based on your response, health status, and current dose. Dr. Jaqua evaluates each transition individually.

For patients who have plateaued and are evaluating next steps, a consultation to discuss the transition — including what the clinical expectations are and how Vitality manages the process — is the right starting point. See candidacy criteria for semaglutide for context on who typically benefits from GLP-1 therapy.

Comparison at a Glance

Individual results vary. Trial averages reflect population data under controlled conditions, not guaranteed outcomes for any individual. All pricing reflects publicly available manufacturer list prices as of 2025.

Frequently Asked Questions

Conclusion

Both semaglutide and tirzepatide represent genuine advances in physician-supervised weight loss medicine. The SURMOUNT-5 head-to-head trial provides the clearest available clinical evidence for how they compare. For most patients, the right choice is determined through physician evaluation — not by picking the medication with the higher trial average and hoping for the best.

At Vitality Texas, both medications are available through our physician-supervised medical weight loss program. Your free initial consultation includes a full evaluation to determine which option best fits your clinical picture, goals, and health history. There is no commitment at that stage.